Section Arrow
NKTX.NASDAQ
- Nkarta
Quotes are at least 15-min delayed:2025/03/28 00:17 EDT
Last
 1.97
+0.6 (+43.80%)
Day High 
2.34 
Prev. Close
1.37 
1-M High
1.95 
Volume 
27.28M 
Bid
1.96
Ask
1.97
Day Low
1.52 
Open
1.53 
1-M Low
1.31 
Market Cap 
96.68M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.54 
20-SMA 1.65 
50-SMA 2.01 
52-W High 11.8388 
52-W Low 1.31 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.83/-2.75
Enterprise Value
178.95M
Balance Sheet
Book Value Per Share
6.11
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 00:17 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.